The low approval rate of anticancer drugs in the cancer industry is due to the inaccuracy of preclinical models to clinical trials. Models such as 3D in vitro models have become a viable option since it is more customizable, especially since they can be 3D bioprinted. The use of biomaterials in 3D bioprinting has become an exciting alternative to tissue engineering and regenerative medicine…